scispace - formally typeset
Journal ArticleDOI

Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

Reads0
Chats0
TLDR
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Abstract
Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR 16 ) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) defined remission; a QIDS-SR 16 total score of ≥11 (HRSD 17 ≥14) defined relapse. Results: The QIDS-SR 16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, t...

read more

Citations
More filters
Journal ArticleDOI

Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

TL;DR: A highly consistent pattern of Glx-level reductions in major depressive disorder and elevations in bipolar disorder is found and these patterns suggest that the glutamate-related metabolite pool is constricted in major depressed disorder and expanded inipolar disorder.
Journal ArticleDOI

Glial pathology in an animal model of depression: Reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole

TL;DR: This study provides the first experimental evidence that chronic stress impairs cortical glial function and provides further validation of hypothesis that glial dysfunction and disrupted amino-acid neurotransmission contribute to the pathophysiology of depression and that modulation of glutamate metabolism, uptake and/or release represent viable targets for antidepressant drug development.
Journal ArticleDOI

Dopamine System Dysregulation in Major Depressive Disorders.

TL;DR: This review explores the current information regarding the afferent modulation of the dopaminergic system and its relevance to major depressive disorder, as well as some of the system-level effects of novel antidepressants such as agomelatine and ketamine.
Journal ArticleDOI

Electroconvulsive therapy for depression.

TL;DR: An 82-year-old woman with severe depression, including psychotic symptoms, is referred for consideration of electroconvulsive therapy.
Journal ArticleDOI

Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial.

TL;DR: Findings confirm earlier reports of the antidepressant efficacy and safety of tDCS and Vigilance for mood switching is advised when administering tDCS to individuals with bipolar disorder.
References
More filters
Journal ArticleDOI

Cumulative illness rating scale.

TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.
Journal ArticleDOI

The Inventory of Depressive Symptomatology (IDS): Psychometric properties.

TL;DR: Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.
Related Papers (5)